Editas MedicineEDIT

Key highlights

• Extended cash runway: The company now expects its $190.2 million in cash to last into the second half of 2028, a significant jump from previous projections that only reached Q2 2027. This provides several years of safety for the business to fund its operations through key clinical trial readouts.
• Stronger licensing revenue: Collaboration and research revenue rose to $10.4 million from $7.5 million a year ago, primarily because of a milestone payment from partner Bristol Myers Squibb. This revenue is vital because it helps offset the high costs of developing new genetic medicines.
• Lower research spending: Research and development costs fell to $21.2 million, which is well below the $47.6 million spent in the same period two years ago. The company achieved this by lowering employee costs and external research spending even as it paid higher license fees for its core technology.
• Clinical progress on track: Editas received regulatory approval in Australia to begin its first human study for EDIT-401, a treatment for high cholesterol, and plans to start dosing patients this year. Early data from primates showed that the drug maintained a 90% reduction in bad cholesterol over 10 months, suggesting the treatment could be effective over long periods.
• Trial data timeline confirmed: Management expects to report the first safety data from its cholesterol study in the first quarter of 2027, followed by main efficacy results in the second half of 2027. These results will be the primary factor in determining if the drug is ready for larger, more expensive final-stage trials.

Our take: This was a very strong quarter for a biotech at this stage. Editas managed to extend its cash runway by more than a year while hitting its clinical milestones and keeping spending under control. This stability significantly strengthens the long-term case as the company moves into human testing.